Cetuximab Reduces the Accumulation of Radiolabeled Bevacizumab in Cancer Xenografts without Decreasing VEGF Expression

Autor: Otto C. Boerman, Hanneke W. M. van Laarhoven, Sandra Heskamp, Mallory S. Engelhardt, Janneke D.M. Molkenboer-Kuenen, Anneke Geurts-Moespot, Fred C.G.J. Sweep, Winette T. A. van der Graaf, Wim J.G. Oyen

Publikováno v: Molecular Pharmaceutics, 11, 4249-4257
Molecular Pharmaceutics, 11, pp. 4249-4257
Molecular pharmaceutics, 11(11), 4249-4257. American Chemical Society

Item does not contain fulltext Introduction: Bevacizumab and cetuximab are approved for the treatment of cancer. However, in advanced colorectal cancer, addition of cetuximab to chemotherapy with bevacizumab did not improve survival. The reason for t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4694f05f156b7674ec907939f29721da
https://doi.org/10.1021/mp500460g